Tuesday, December 5, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Professor of Medicine
Medical Director, Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL
Department of Internal Medicine III
Ulm University
Ulm, Germany
Associate Professor
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Professor of Medicine
Division of Hematology
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio, United States
Professor
Head, Lymphoma Group
Lymphoma and Chronic Lymphoproliferative Syndromes Unit
Institute of Hematology "L. e A. Serà gnoli"
University of Bologna
Bologna, Italy
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This activity is intended for hematologists/oncologists who manage patients with CLL.
The goal of this activity is that learners will be able to apply expert feedback on the latest data on BTK inhibitors for relapsed/refractory (R/R) CLL and their implications for the evolving treatment paradigm.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Professor of Medicine
Medical Director, Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL
Department of Internal Medicine III
Ulm University
Ulm, Germany
Associate Professor
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Professor of Medicine
Division of Hematology
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio, United States
Professor
Head, Lymphoma Group
Lymphoma and Chronic Lymphoproliferative Syndromes Unit
Institute of Hematology "L. e A. Serà gnoli"
University of Bologna
Bologna, Italy
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.50
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of
continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the
time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the
valid credit period that
is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in
your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as
the certificates from the
CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 8/24/2022
Valid for credit through: 8/24/2023, 11:59 PM EST
processing....
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
